GlassScriptPhysician profile
Frans Geeraerts
NPI 1053490300
$1,445.97
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $317 · 2021: $456.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $257.77 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $235.54 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $197.50 | 2019-2021 | |
| Allergan, INC. | $175.73 | 2019-2020 | |
| Lundbeck LLC | $172.16 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.79 | 2021 | |
| Neurocrine Biosciences, INC. | $82.06 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $74.32 | 2019-2021 | |
| Abbvie INC. | $37.65 | 2021 | |
| Eisai INC. | $17.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.27 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.17 | 2021 | |
| Noven Therapeutics, LLC | $15.08 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.18 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $7.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frans Geeraerts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.